The Mycoplasma Testing Market size was valued USD 802 million in 2021 and is expected to reach USD 2.31 billion by 2030 at 14.1% CAGR during the forecast period 2022-2030. In the realm of biopharmaceuticals, ensuring product safety and efficacy is paramount. Mycoplasma contamination poses a significant risk to biologics manufacturing, with potentially devastating consequences for both patients...